There’s a lot of buzz these days around the role that AI will play in pharmaceutical R&D – from target identification to therapeutic design and optimization, from patient stratification to clinical trial design and site selection, and beyond.
So what’s real, and what’s just hype?
Join us for an engaging panel discussion – featuring representatives from the pharmaceutical industry, the startup world and the investor community – focused on how AI is driving the discovery, development and delivery of innovative medicines today, and what the future holds in this rapidly-evolving space. Followed by an exciting celebratory reception to commemorate JLABS @ NYC 6-Year Anniversary!
4PM Registration Opens
4:30PM Opening Remarks
Tingting Zhang-Kharas | Head, JLABS US Northeast, Johnson & Johnson Innovation
Welcome remarks with a highlight of how JLABS helps start ups and entrepreneurs scale their innovations.
4:35PM Data Science Innovation at Johnson & Johnson
Dave Apfel | Head, External Innovation, R&D Data Science and Digital Health, Innovative Medicine, Johnson & Johnson
A presentation on how Johnson & Johnson innovates in Data Science including what our priorities are in the space.
4:45PM Panel Discussion - How AI is Transforming Pharmaceutical R&D
Moderator
Dave Apfel | Head, External Innovation, R&D Data Science and Digital Health, Innovative Medicine, Johnson & Johnson
Panelists
Ariel Katz | CEO & Co-Founder, H1
Liz Schwarzbach | Chief Business Officer, BigHat Biosciences
Ginger Liau | Partner, Bio Fund, a16z
An engaging panel discussion on how AI can help to advance therapeutic discovery, clinical trial diversity, clinician relations, and more.
5:15PM Q&A Session
5:30PM JLABS @ NYC Anniversary Reception Sponsored by A.Team
7PM Program Close
Ariel Katz is the CEO and Co-founder of H1 the leading healthcare platform that connects the world to the right doctors. H1 supports the top Pharma and BioTech companies with AI-powered insights that help Medical Affairs and Clinical Operations accelerate drug discovery and commercialization. Ariel previously co-founded ResearchConnection, acquired by the Jefferson Accelerator Fund, Gates Foundation & Kauffman Foundation. Named to Forbes '30 under 30, he co-founded H1 to address the need of aggregating everything there is to know about doctors in one accessible platform.
David Apfel is the Head of External Innovation for R&D Data Science and Digital Health at Johnson & Johnson Innovative Medicine, where he focuses on creating partnerships that leverage AI/ML across discovery & clinical development. David previously built and led the R&D Data Science Immunology team, working to identify and deliver use-cases to advance J&J’s immunology portfolio. Before joining J&J, David worked in healthcare consulting at The Boston Consulting Group and in global health at the Clinton Health Access Initiative. He holds a BA in Mathematical-Economics from Pomona College and an MBA from NYU Stern.
Tingting has responsibility for all aspects of the JLABS @ NYC, Boston, and Philadelphia, as well as supporting the broader ecosystem through external presence and partnerships. She is responsible for sourcing and leading diligence for JLABS applicants and prospective companies in alignment with J&J focus areas to ensure strategic fit. She collaborates with the broader JJI team to enable partnerships between J&J and JLABS companies to strengthen the innovation pipeline. She leads the team support JLABS Northeast US, with responsibility for JLABS @ NYC site operations and budget, as well as our JLABS @ LabCentral in Boston and our JLABS activities in Philadelphia.
Tingting joined the JLABS team from IPSEN, where she managed the Oncology External Innovation team as a Senior Director, leading the team to identify and assess global business development opportunities in the oncology field.
Prior to IPSEN, Tingting held key roles in the Oncology Search and Evaluation team at Loxo Oncology at Eli Lilly, where she spearheaded the evaluation of a variety of oncology companies and assets for partnering and venture capital investment considerations, and managed academic research collaborations, leading to multiple in-licensing, out-licensing, and acquisition deals.
In her earlier career, Tingting had extensive experience in biopharma consulting at Navigant as a Senior Consultant and in technology transfer and business development at Memorial Sloan Kettering Cancer Center as a Licensing Manager.
With an exceptional track record throughout her past roles, Tingting is passionate about identifying and supporting innovations in the life science industry, particularly within the NYC region. She received her Ph.D. in Immunology from Harvard University and Bachelor of Medical Sciences from Peking University Health Science Center.
Elizabeth has over 20 years of experience in biopharma and academia drug discovery and development. She found her passion for pharmacology as a biologist in Merck Research Labs, later completing her doctorate in neuropharmacology at the University of Pennsylvania School of Medicine. After gaining growth, portfolio, and investment strategy experience at L.E.K. Consulting’s Life Sciences practice, she transitioned to GlaxoSmithKline R&D Strategy team. Most recently, Elizabeth served as the Chief Business Officer at the New York Stem Cell Foundation (NYSCF) Research Institute.
Ginger Liau is a partner on the Bio + Health team focused on biotech. She leads business development for the a16z life sciences portfolio. Prior to joining Andreessen Horowitz, Ginger worked at Alnylam Pharmaceuticals where she held a variety of positions across the business. She was an RNA chemist before moving into strategy and operations roles in business planning, program management, and investor relations. Ginger earned her undergraduate degree in Chemistry and Math from Vanderbilt University and her MBA from Stanford Graduate School of Business.
Amy is the Chief Revenue Officer at A.Team, a leading technology enabled talent services company. She has spent over 27 years in the high tech and services industry leading Product, Sales and Marketing organizations at both large tech companies such as Siebel Systems, Microsoft and Google as well as as Venture and PE backed growth stage companies to implement transformation for scaled growth across organizations. Her expertise is in business transformation through technology and driving business growth. She earned her MBA from Kellogg School of Management at Northwestern University.
Johnson & Johnson Innovation – JLABS Notice
The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them. By hosting this event, the presentations and any associated networking and/or individual meetings, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information
